EMPagliflozin after Aortic Valve Replacement study: a randomized clinical trial

28 August 2026 (14:30 - 14:45)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Louise Marqvard Soerensen

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail

EuroHeart - TAVI Registry

Professor R. Kharbanda (Oxford, GB)

Presentation thumbnail

Optimal Medical Treatment With or Without Valve Repair in Patients with symptomatic Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: a multicenter, randomized comparison

Professor J. Mehilli (Landshut, DE)

Presentation thumbnail

Efficacy and safety of routine post-dilatation using a balloon-expandable transcatheter aortic valve implantation platform - the randomized controlled DUOTAP trial.

Doctor M. Autherith (Vienna, AT)

Presentation thumbnail

Prosthesis-Patient Mismatch after Transcatheter or Surgical Treatment of Aortic Valve Stenosis: A Sub-Study of the Randomized DEDICATE-DZHK6 Trial

Doctor T. Rheude (Munich, DE)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: valvular heart disease

The Event

Event poster

ESC Congress 2026

28 August 2026 14:30 CET

You may be interested in

Congress Presentation

Association of SGLT2-inhibitor and GLP1-receptor agonist use with clinical outcomes in aortic stenosis: a large-scale propensity-matched study

28 August 2026

Congress Presentation

Empagliflozin in patients with acute myocardial infarction.

29 August 2022

Congress Presentation

DapaTAVI: dapagliflozin in patients undergoing transcatheter aortic valve implantation

31 August 2025

Congress Session

Innovation and integration in cardiovascular medicine

1 September 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources